caa a22 4500 467949751 CHVBK 20180405193741.0 cr unu---uuuuu 170328e20040101xx s 000 0 eng 10.1007/BF02665359 doi (NATIONALLICENCE)springer-10.1007/BF02665359 (NATIONALLICENCE)springer-10.1007/s00280-003-0711-z Pharmacokinetics of etoposide in cancer patients treated with high-dose etoposide and with dexrazoxane (ICRF-187) as a rescue agent [Elektronische Daten] [Patricia Schroeder, Kenneth Hofland, Peter Jensen, Maxwell Sehested, Seppo Langer, Brian Hasinoff] Purpose: The pharmacokinetics of etoposide were studied in cancer patients with brain metastases treated with high-dose etoposide in order to determine if the pharmacokinetics were altered by the use of dex-razoxane as a rescue agent to reduce the extracerebral toxicity of etoposide.Methods: Etoposide plasma levels were determined by HPLC.Results: The etoposide pharmacokinetics described by a monophasic first-order elimination model were found to be similar to other reported data in other settings and at similar doses.Conclusions: The pharmacokinetics of etoposide were unaffected by dexrazoxane rescue. Springer-Verlag, 2003 AUC 0−∞ : Area under the curve from time zero to infinity nationallicence C max : Maximum plasma concentration of drug nationallicence Cl tot : Total plasma clearance nationallicence HPLC : High-pressure liquid chromatography nationallicence P oct : Octanol-water partition coefficient nationallicence t 1/2β : Beta phase plasma elimination half-time nationallicence t r : Retention time nationallicence Etoposide nationallicence Dexrazoxane nationallicence Pharmacokinetics nationallicence Toxicity nationallicence Rescue nationallicence Schroeder Patricia Faculty of Pharmacy, University of Manitoba, 50 Sifton Road, R3T 2N2, Winnipeg, Manitoba, Canada aut Hofland Kenneth Laboratory of Experimental Medical Oncology, The Laboratory Center, The National University Hospital, 2100, Copenhagen, Denmark aut Jensen Peter Laboratory of Experimental Medical Oncology, The Laboratory Center, The National University Hospital, 2100, Copenhagen, Denmark aut Sehested Maxwell The Finsen Center and Department of Pathology, The National University Hospital, 2100, Copenhagen, Denmark aut Langer Seppo Laboratory of Experimental Medical Oncology, The Laboratory Center, The National University Hospital, 2100, Copenhagen, Denmark aut Hasinoff Brian Faculty of Pharmacy, University of Manitoba, 50 Sifton Road, R3T 2N2, Winnipeg, Manitoba, Canada aut Cancer Chemotherapy and Pharmacology Springer-Verlag 53/1(2004-01-01), 91-93 0344-5704 53:1<91 2004 53 280 https://doi.org/10.1007/BF02665359 text/html Onlinezugriff via DOI 1 brief-communication jats NATIONALLICENCE 856 40 https://doi.org/10.1007/BF02665359 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Schroeder Patricia Faculty of Pharmacy, University of Manitoba, 50 Sifton Road, R3T 2N2, Winnipeg, Manitoba, Canada aut NATIONALLICENCE 700 1- Hofland Kenneth Laboratory of Experimental Medical Oncology, The Laboratory Center, The National University Hospital, 2100, Copenhagen, Denmark aut NATIONALLICENCE 700 1- Jensen Peter Laboratory of Experimental Medical Oncology, The Laboratory Center, The National University Hospital, 2100, Copenhagen, Denmark aut NATIONALLICENCE 700 1- Sehested Maxwell The Finsen Center and Department of Pathology, The National University Hospital, 2100, Copenhagen, Denmark aut NATIONALLICENCE 700 1- Langer Seppo Laboratory of Experimental Medical Oncology, The Laboratory Center, The National University Hospital, 2100, Copenhagen, Denmark aut NATIONALLICENCE 700 1- Hasinoff Brian Faculty of Pharmacy, University of Manitoba, 50 Sifton Road, R3T 2N2, Winnipeg, Manitoba, Canada aut NATIONALLICENCE 773 0- Cancer Chemotherapy and Pharmacology Springer-Verlag 53/1(2004-01-01), 91-93 0344-5704 53:1<91 2004 53 280 NATIONALLICENCE 856 40 https://doi.org/10.1007/s00280-003-0711-z text/html Onlinezugriff via DOI Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer NATIONALLICENCE NATIONALLICENCE NL-springer